Enveric Biosciences (ENVB) Exchange Rate Effect (2016 - 2026)
Enveric Biosciences (ENVB) posted Exchange Rate Effect of -$15091.0 for Q1 2026, down 196.65% sequentially from $15614.0 in Q4 2025, and down 284.68% YoY from $8171.4 in Q1 2025.
Enveric Biosciences (ENVB) Exchange Rate Effect (2016 - 2026) Analysis & Trends
Enveric Biosciences has reported Exchange Rate Effect for 11 years, with the latest figure at -$15091.0 in Q1 2026.
- Quarterly Exchange Rate Effect fell 284.68% year-over-year to -$15091.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12667.0 (down 88.89% YoY) and the FY2025 annual result came in at -$1499.0, down 128.0% from the prior year.
- Exchange Rate Effect declined to -$15091.0 in Q1 2026 per ENVB's latest filing, from $15614.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $30573.0 in Q3 2023 and troughed at -$63120.0 in Q3 2022.
- A 5-year average of -$6036.6 and a median of -$4534.0 in 2022 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2023 and 2025: Exchange Rate Effect jumped 556.97% in 2023, then sank 384.02% in 2025.
- Over 5 years, Exchange Rate Effect stood at -$8810.0 in 2022, then slumped by 370.16% to -$41421.0 in 2023, then surged by 45.54% to -$22556.0 in 2024, then jumped by 169.22% to $15614.0 in 2025, then plunged by 196.65% to -$15091.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$15091.0, $15614.0, and -$9617.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -2.45 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -287,000.00 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.63 Mn |
| 10 | Enveric Biosciences | 5.42 Mn | -2.87 Mn | - | -12,933.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15,091.00 |
| Mar 31, 2026 | -15,091.00 |
| Dec 31, 2025 | 15,614.00 |
| Dec 31, 2025 | 15,614.00 |
| Sep 30, 2025 | -9,617.00 |
| Sep 30, 2025 | -9,617.00 |
| Jun 30, 2025 | -3,573.00 |
| Jun 30, 2025 | -3,573.00 |
| Mar 31, 2025 | -3,923.00 |
| Mar 31, 2025 | -3,923.00 |
| Dec 31, 2024 | -22,556.00 |
| Dec 31, 2024 | -22,556.00 |
| Sep 30, 2024 | 18,515.00 |
| Sep 30, 2024 | 18,515.00 |
| Jun 30, 2024 | 1,258.00 |
| Jun 30, 2024 | 1,258.00 |
| Mar 31, 2024 | 8,137.00 |
| Mar 31, 2024 | 8,137.00 |
| Dec 31, 2023 | -41,421.00 |
| Dec 31, 2023 | -41,421.00 |